We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+47.5%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow %
91.48%
Top 10 Hldgs %
25%
Holding
94
New
94
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
IRD
Opus Genetics
IRD
+$14.3M
2
ANAB icon
AnaptysBio
ANAB
+$6.34M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.78M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.47M
5
INSM icon
Insmed
INSM
+$5.43M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 85.32%
2 Technology 2.23%
3 Consumer Staples 1.19%
4 Financials 1.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHRS icon
26
Coherus Oncology
CHRS
$210M
$3.77M 1.41%
+216,925
New +$3.86M
PTGX icon
27
Protagonist Therapeutics
PTGX
$9.37B
$3.75M 1.4%
+185,854
New +$4M
IMUX icon
28
Immunic
IMUX
$206M
$3.73M 1.39%
+24,416
New +$4.38M
IMVT icon
29
Immunovant
IMVT
$8.06B
$3.58M 1.34%
+77,622
New +$3.59M
LNTH icon
30
Lantheus
LNTH
$6.59B
$3.54M 1.32%
+262,465
New +$3.44M
CRDF icon
31
Cardiff Oncology
CRDF
$75.9M
$3.34M 1.25%
+185,552
New +$3.26M
KDNY
32
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.26M 1.22%
+205,799
New +$3.1M
TIO
33
DELISTED
Tingo Group, Inc. Common Stock
TIO
$3.19M 1.19%
+1,533,425
New +$3.41M
VINC
34
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$3.14M 1.17%
+7,508
New +$2.37M
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
$3.11M 1.16%
+465,589
New +$2.91M
HAE icon
36
Haemonetics
HAE
$3.9B
$3.1M 1.16%
+26,144
New +$2.81M
SCYX icon
37
SCYNEXIS
SCYX
$54.6M
$3.06M 1.14%
+50,000
New +$2.34M
OIG
38
DELISTED
Orbital Infrastructure Group, Inc. Common Stock
OIG
$2.96M 1.11%
+33,850
New +$1.45M
SIEN
39
DELISTED
Sientra, Inc.
SIEN
$2.93M 1.09%
+75,263
New +$3.37M
AHACU
40
DELISTED
Alpha Healthcare Acquisition Corp Unit
AHACU
$2.91M 1.09%
+275,000
New +$2.76M
MLTX icon
41
MoonLake Immunotherapeutics
MLTX
$1.55B
$2.84M 1.06%
+250,000
New +$2.65M
NNDM
42
Nano Dimension
NNDM
$341M
$2.77M 1.03%
+304,600
New +$1.55M
SNCE
43
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.67M 1%
+12,500
New +$2.6M
CHFW.U
44
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$2.62M 0.98%
+250,000
New +$2.55M
TMPMU
45
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$2.61M 0.97%
+254,000
New +$2.57M
FSDC
46
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$2.57M 0.96%
+234,000
New +$2.41M
EIGR
47
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.43M 0.91%
+6,583
New +$1.89M
SRSAU
48
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$2.4M 0.89%
+225,000
New +$2.32M
CMLFU
49
DELISTED
CM Life Sciences, Inc. Unit
CMLFU
$2.32M 0.87%
+200,000
New +$2.15M
TCRR
50
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.29M 0.85%
+73,991
New +$1.87M
1
2
3 4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CF
Crosspoint Financial Tustin, California $39.8M AUM 14.13% 1-Year Est. Return

Altium Capital Management's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Altium Capital Management, which disclosed 94 positions worth $268M. Its ten largest holdings account for 25% of the portfolio.

Its largest position is Opus Genetics: 2,068,530 shares worth $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, followed by Technology and Consumer Staples.

  • Altium Capital Management's largest Q4 2020 buy was Opus Genetics: 2,068,530 shares worth $13.4M.
  • Altium Capital Management's ten largest holdings make up 25% of its $268M portfolio in Q4 2020.
  • Altium Capital Management disclosed 94 positions in Q4 2020, its first 13F filing on record.

Based on Altium Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.